Nowadays, heart transplantation takes its place as the most effective treatment for end-stage heart failure. Globally, an annual average of 5000 heart transplantations are performed [1]. Improvements in current treatment modalities and immunosuppression therapies have significantly improved postoperative survival. However, despite these advancements, transplant recipients remain vulnerable to early...

Sicim Hüseyin et al.
Journal of Cardiothoracic Surgery 2024; 19(1): 312
Lire la suite

Solid-organ transplant recipients are at high risk of severe coronavirus disease 2019 (COVID-19) as they undergo long-term immunosuppressive therapy [1]. Nirmatrelvir/ritonavir (NMV/RTV) is the first oral drug for COVID-19 approved in Japan, and RTV is a potent inhibitor of cytochrome P450 (CYP) 3A [2]. Therefore, scrutinizing drug–drug interactions during administration of concomitant medications...

Naganawa Hanako et al.
Journal of Pharmaceutical Health Care and Sciences 2024; 10(1): 37
Lire la suite

Patients with end-stage renal disease (ESRD) are optimally treated with kidney transplantation (KTx) [1] because it is associated with better quality of life and longer life expectancy [2]. Although patient and graft survival have considerably increased following KTx in recent decades, KTx recipients still have a lower survival rate than healthy individuals because of organ dysfunction and graft loss...

Ramouz Ali et al.
BioMed Research International 2022 (2022), Article ID 8949919, 7 pages
Lire la suite